Asiaticobdella Hirudin-1
Putative hirudin-like factor with RGD motif from African medicinal leech — dual thrombin-inhibitor / integrin-binder mechanism unique to A. fenestrata.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Putative hirudin-like factor with RGD motif from African medicinal leech — dual thrombin-inhibitor / integrin-binder mechanism unique to A. fenestrata.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
This putative hirudin's in vitro thrombin-binding activity does NOT establish clinical efficacy of whole-leech therapy. No FDA-approved derivative exists; A. fenestrata is taxonomically distinct from the FDA-cleared K040187 medicinal leech species.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 7,000 Da
- Source species
- Asiaticobdella fenestrata
- Discovered
- 2025 · Schulz L et al.
Biological Targets
- → thrombin (Factor IIa) + platelet integrin (via N-terminal RGD)
Key Citations
- Schulz L et al. (2025), Parasitol Res · PMID 41198932
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.